Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Beam Therapeutics Inc.
Headquarters: Cambridge, MA, United States of America
Website: https://beamtx.com
Year Founded: 2017
Status: Public
Industry Sector: HealthTechnology
CEO: John Evans, MBA
Number Of Employees: 483
Enterprise Value: $1,352,047,598
PE Ratio: -3.6
Exchange/Ticker 1: NASDAQ:BEAM
Exchange/Ticker 2: N/A
Latest Market Cap: $1,643,366,400
BioCentury | Mar 14, 2025
Finance
Insilico, Lila draw nine-figure venture rounds: Finance Report
Plus: public companies Beam, Tarsus and Mineralys raise follow-ons
BioCentury | Mar 12, 2025
Discovery & Translation
Science Spotlight: Killing the mesenchymal precursors that drive cancer progression
BioCentury’s roundup of translational innovations also includes blood detection of pregnancy complications, BBB-crossing antibodies, and more
BioCentury | Mar 12, 2025
Product Development
Oral peptide win for Protagonist/J&J, Beam’s base editor POC, and more: Clinical Report
Protagonist data led to week’s biggest share price gain, while Arvinas saw biggest loss: in BioCentury’s latest Clinical Report
BioCentury | Feb 4, 2025
Product Development
Gene editing companies to gain from FDA’s platform designation update
An upcoming eligibility expansion a gene editing opportunity, but leaves AAVs in the dark
BioCentury | Jan 18, 2025
Product Development
2025 catalysts: New modality showdowns
Genetic therapies compete in the same indications, as degraders come of age
BioCentury | Dec 10, 2024
Product Development
Gene and base editors deliver on fetal hemoglobin expression: ASH24
Editas, Beam report updates on sickle cell genetic therapies at this year’s ASH meeting
BioCentury | Dec 5, 2024
Discovery & Translation
Science Spotlight: Advances in RSV and hMVP vaccines
BioCentury’s roundup of translational innovation also features a kinase degrader for breast cancer, and half a dozen papers on product candidates
BioCentury | Nov 5, 2024
Product Development
Arcus data the latest twist in the TIGIT story
BioCentury’s Clinical Report also analyzes the impact of a patient death in Beam’s trial, plus data from Cogent, Disc, Essa and Novo
BioCentury | Oct 22, 2024
Finance
Venture funds, a new chapter for MS & Wave’s data: a BioCentury podcast
What Forbion’s $2.2B raise says about the state of venture, NIH’s Daniel Reich on MS and RNA-editing oligo data from Wave
BioCentury | Oct 17, 2024
Product Development
Wave data propel RNA-editing stocks, but are all platforms created equal?
In first human RNA-editing data, Wave reports positive results from WVE-006 in alpha-1 antitrypsin deficiency
Items per page:
1 - 10 of 108